Skip to main content
Premium Trial:

Request an Annual Quote

PGDx Gets IDE For Tissue NGS Test in Merck Immunotherapy Trial

NEW YORK – Personal Genome Diagnostics said today that it has received an Investigational Device Exemption (IDE) approval from the US Food and Drug Administration for the use of its elio tissue complete assay in a Merck trial of pembrolizumab-based combination therapy. 

Elio tissue complete, a 507-gene NGS test that detects all classes of gene alterations and also reads out measures of microsatellite instability and tumor mutation burden, is being used in the trial to direct patient enrollment and stratification.

PGDx performs the assay in its CAP/CLIA certified laboratory and has also developed a kit version for which it hopes to garner FDA approval for clinical use across customer laboratories. Over the last year, the company has shifted its strategy away from in-house clinical testing to serving mainly pharma customers through its own lab while preparing to launch elio tissue and plasma IVDs.

Most recently, it announced that the elio tissue complete kit had received a CE mark enabling it to be marketed in Europe and other countries that recognize the CE mark. Its complementary liquid biopsy version met the same milestone last March. Neither have yet been endorsed by the FDA for clinical use, however.

PGDx CEO Doug Ward said in a statement that the agency's decision to grant the IDE for elio tissue in its work with Merck "validates the robustness of the test and reinforces the role of diagnostic biomarkers in investigating treatment strategies for patients living with cancer." 

The company previously announced it was working with Merck, saying this January that it would test patients in the enrollment portion of the company's phase II KeyImpact study, exploring pembrolizumab (Keytruda) combination strategies.

John Simmons, PGDx's VP of translational medicine, confirmed today that the new IDE is for this same frontline lung cancer trial. Having it in place means that the elio test can also provide for certain exclusion criteria in the trial, which include the presence of alterations associated with ALK, EGFR, BRAF, and ROS1 in approved targeted therapies. Prior to the exemption, patients recruited to the trial would have had to have in hand other existing test results indicating that they did not carry one of these alterations.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.